tetano
Editor, Senior Moderator
Eur J Pharmacol
. 2020 Sep 18;173568.
doi: 10.1016/j.ejphar.2020.173568. Online ahead of print.
A review of medications used to control and improve the signs and symptoms of COVID-19 patients
Kiavash Hushmandi[SUP] 1 [/SUP], Saied Bokaie[SUP] 2 [/SUP], Mehrdad Hashemi[SUP] 3 [/SUP], Ebrahim Rahmani Moghadam[SUP] 4 [/SUP], Mehdi Raei[SUP] 5 [/SUP], Farid Hashemi[SUP] 6 [/SUP], Mahdi Bagheri[SUP] 7 [/SUP], Solomon Habtemariam[SUP] 8 [/SUP], Seyed Mohammad Nabavi[SUP] 9 [/SUP]
Affiliations
Abstract
In December 2019, an unprecedented outbreak of pneumonia associated with a novel coronavirus disease 2019 (COVID-19) emerged in Wuhan City, Hubei province, China. The virus that caused the disease was officially named by the World Health Organization (WHO) as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the high transmission rate of SARS-CoV-2, it became a global pandemic and public health emergency within few months. Since SARS-CoV-2 is genetically 80% homologous with the SARS-CoVs family, it is hypothesized that medications developed for the treatment of SARS-CoVs may be useful in the control and management of SARS-CoV-2. In this regard, some medication being tested in clinical trials and in vitro studies include anti-viral RNA polymerase inhibitors, HIV-protease inhibitors, anti-inflammatory agents, angiotensin converting enzyme type 2 (ACE 2) blockers, and some other novel medications. In this communication, we reviewed the general characteristics of medications, medical usage, mechanism of action, as well as SARS-CoV-2 related trials.
Keywords: Medications; Novel corona virus; SARS-CoV-2.
. 2020 Sep 18;173568.
doi: 10.1016/j.ejphar.2020.173568. Online ahead of print.
A review of medications used to control and improve the signs and symptoms of COVID-19 patients
Kiavash Hushmandi[SUP] 1 [/SUP], Saied Bokaie[SUP] 2 [/SUP], Mehrdad Hashemi[SUP] 3 [/SUP], Ebrahim Rahmani Moghadam[SUP] 4 [/SUP], Mehdi Raei[SUP] 5 [/SUP], Farid Hashemi[SUP] 6 [/SUP], Mahdi Bagheri[SUP] 7 [/SUP], Solomon Habtemariam[SUP] 8 [/SUP], Seyed Mohammad Nabavi[SUP] 9 [/SUP]
Affiliations
- PMID: 32956644
- DOI: 10.1016/j.ejphar.2020.173568
Abstract
In December 2019, an unprecedented outbreak of pneumonia associated with a novel coronavirus disease 2019 (COVID-19) emerged in Wuhan City, Hubei province, China. The virus that caused the disease was officially named by the World Health Organization (WHO) as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the high transmission rate of SARS-CoV-2, it became a global pandemic and public health emergency within few months. Since SARS-CoV-2 is genetically 80% homologous with the SARS-CoVs family, it is hypothesized that medications developed for the treatment of SARS-CoVs may be useful in the control and management of SARS-CoV-2. In this regard, some medication being tested in clinical trials and in vitro studies include anti-viral RNA polymerase inhibitors, HIV-protease inhibitors, anti-inflammatory agents, angiotensin converting enzyme type 2 (ACE 2) blockers, and some other novel medications. In this communication, we reviewed the general characteristics of medications, medical usage, mechanism of action, as well as SARS-CoV-2 related trials.
Keywords: Medications; Novel corona virus; SARS-CoV-2.